Evidence map›Paper›PMID 36244871›Full record

ArticleHuman immunology2023

Accommodation in allogeneic and xenogeneic organ transplantation: Prevalence, impact, and implications for monitoring and for therapeutics.

Jeffrey L Platt, Marilia Cascalho

Open access · greenAbstract read
In one paragraph

Article in Human immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Antibody-mediated rejection-treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jeffrey L PlattDepartments of Surgery and of Microbiology & Immunology, University of Michigan, Ann Arbor, MI, United States. Electronic address: plattjl@umich.edu.
Marilia CascalhoDepartments of Surgery and of Microbiology & Immunology, University of Michigan, Ann Arbor, MI, United States.
University of Michigan–Ann Arbor · US

Funding

Hepatocyte xenografts for treatment of acute liver failureR01AI122369 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FOX, IRA J., PLATT, JEFFREY L · 2016 to 2020
$5.0M
Donor-specific B cells in Transplantation.R01AI151588 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASCALHO, MARILIA ISABEL, PLATT, JEFFREY L · 2020 to 2025
$2.7M
Immunodeficient Pigs for Stem Cell­-Based Regenerative MedicineR01OD023138 · OD · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI PIEDRAHITA, JORGE A · 2017 to 2020
$1.8M
Accommodation in TransplantationR56AI123262 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASCALHO, MARILIA ISABEL, PLATT, JEFFREY L · 2016 to 2016
$388k
NIAID NIH HHS R01 AI122369NIAID NIH HHS R01 AI151588NIAID NIH HHS R56 AI123262NIH HHS R01 OD023138
6 · The paper itself

Abstract

Accommodation refers to acquired resistance of organs or tissues to immune or inflammatory reactions that might otherwise cause severe injury or rejection. As first observed in ABO-incompatible kidney transplants and heterotopic cardiac xenografts, accommodation was identified when organ transplants continued to function despite the presence of anti-graft antibodies and/or other reactants in the blood of recipients. Recent evidence suggests many and perhaps most organ transplants have accommodation, as most recipients mount B cell responses specific for the graft. Wide interest in the impact of graft-specific antibodies on the outcomes of transplants prompts questions about which mechanisms confer protection against such antibodies, how accommodation might be detected and whether and how rejection could be superimposed on accommodation. Xenotransplantation offers a unique opportunity to address these questions because immune responses to xenografts are easily detected and the pathogenic impact of immune responses is so severe. Xenotransplantation also provides a compelling need to apply these and other insights to decrease the intensity and toxicity of immunosuppression that otherwise could limit clinical application.

Indexed as

Hematopoietic Stem Cell TransplantationOrgan TransplantationABO Blood-Group SystemAntibodiesGraft RejectionGraft SurvivalHumansPrevalenceTransplantation, HeterologousABO Blood-Group SystemAntibodiesABO-incompatible transplantAccommodationAllograftAntibodyAntibody-mediated rejectionB cellComplementComplement activationEndothelial cell activationHeparan sulfateOrgan transplantRejectionXenograft

Identifiers

PMID36244871
PMCPMC10339678
OpenAlexW4306169192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.